Hongkou Capital

Day Zero Diagnostics Inc. is an infectious disease diagnostics company focused on developing rapid, sequencing-based diagnostics that identify bacterial pathogens and their antibiotic resistance profiles. The company employs advanced technologies such as Blood2Bac, which enhances bacterial DNA recovery from clinical samples, and BacDetect, designed for the swift detection of bacterial DNA. Its Keynome ID algorithm classifies bacterial species, while Keynome g-AST utilizes machine learning for genomic antibiotic susceptibility testing. Additionally, Day Zero maintains MicrohmDB, a comprehensive database that integrates whole genome sequencing data with resistance and susceptibility profiles of clinically relevant pathogens. Founded in 2016 and based in Boston, Massachusetts, Day Zero aims to transform infectious disease diagnostics by providing complete diagnoses—including species identification and antibiotic resistance—within hours, significantly improving treatment outcomes and reducing costs associated with prolonged diagnostic processes.

Amionx specializes in advanced battery safety technology aimed at preventing fires and explosions associated with lithium-ion batteries. Its flagship innovation, Safe Core technology, functions like a circuit breaker, providing protection against overcharging, internal short circuits, and external heat. This technology is versatile, applicable to all battery chemistries, including solid-state batteries, and it maintains battery performance while enhancing safety. Amionx focuses on addressing safety concerns from the core of the battery outward, enabling original equipment manufacturers to reduce the risk of battery-related accidents.